GNH USA

Europe — EMA

Imukin (Recombinant Human Interferon Gamma 1b)

GNH USA supplies Imukin (Recombinant Human Interferon Gamma 1b), a immunomodulator for chronic granulomatous disease and severe malignant osteopetrosis.

Recombinant Human Interferon Gamma 1b

Request sourcing

1
Pack/s

What is Recombinant Human Interferon Gamma 1b?

Recombinant Human Interferon Gamma 1b, the active ingredient in Imukin, is an Interferon presented as a lyophilized powder for injection for subcutaneous use. It is indicated for chronic granulomatous disease and severe malignant osteopetrosis, where it modulates immune function and bone remodeling. GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

What is Recombinant Human Interferon Gamma 1b used for?

Imukin is an interferon‑gamma product that acts on immune‑deficiency and bone‑remodeling pathways. - Chronic granulomatous disease: enhances macrophage killing capacity to reduce recurrent infections. - Severe malignant osteopetrosis: stimulates osteoclast activity to improve bone resorption and alleviate disease severity.

What are the side effects of Recombinant Human Interferon Gamma 1b?

Interferon‑gamma therapy is associated with a range of adverse reactions.

Common Side Effects: - Flu‑like symptoms: fever, chills, and muscle aches. - Injection‑site reactions: redness, swelling, or pain at the site. - Fatigue and headache. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Hematologic abnormalities such as neutropenia or anemia. - Elevated liver enzymes indicating hepatic stress. - Autoimmune phenomena, including lupus‑like syndrome. - Severe allergic reactions or anaphylaxis. - Pulmonary toxicity presenting as dyspnea or interstitial lung changes.

What precautions apply to Recombinant Human Interferon Gamma 1b?

Patients receiving Imukin should be monitored for safety and efficacy. - Blood counts: regularly assess for neutropenia or anemia. - Liver function: monitor transaminases during therapy. - Autoimmune disease: evaluate for new or worsening autoimmune symptoms. - Cardiac status: use cautiously in patients with severe cardiac disease. - Hypersensitivity: discontinue if a serious allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Recombinant Human Interferon Gamma 1b interact with?

Interferon‑gamma can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immune modulation. - High‑dose corticosteroids or other potent immunosuppressants: may diminish therapeutic effect. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding risk.

Moderate Interactions (Monitor Closely): - CYP450 substrates: possible alteration of metabolism. - Antihistamines: may mask fever, a common side effect. - Concurrent interferons or other immunomodulators: additive toxicity risk.

Frequently asked questions

What conditions is Imukin used to treat?+
Imukin, containing recombinant human interferon‑gamma, is approved for the treatment of chronic granulomatous disease, a primary immunodeficiency, and severe malignant osteopetrosis, a rare bone disorder characterized by excessive bone density.
How does recombinant human interferon gamma work in the body?+
The molecule binds to interferon‑gamma receptors on immune cells, activating the JAK‑STAT pathway. This leads to increased expression of major histocompatibility complex molecules, enhanced macrophage antimicrobial activity, promotion of Th1 immune responses, and stimulation of osteoclast differentiation, which together address the underlying disease processes.
What is the usual dose of Imukin?+
The specific dose and dosing schedule of Imukin are determined by the prescribing clinician based on the patient’s age, weight, disease severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing adverse effects.
Is Imukin safe to use during pregnancy or while breastfeeding?+
The safety of Imukin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after careful consideration.
How do I order Imukin from GNH USA?+
To place an order, submit an enquiry on the Imukin product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.
How does Imukin compare with other interferon therapies?+
Imukin (interferon‑gamma) differs from interferon‑alpha or beta products in its target receptor and immunologic effects. While interferon‑alpha primarily enhances antiviral defenses, interferon‑gamma specifically activates macrophages and promotes Th1‑type immunity, making it the preferred choice for conditions like chronic granulomatous disease and malignant osteopetrosis.
What are the storage requirements for Imukin?+
Imukin should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the lyophilized powder. Do not use the product if it has been exposed to temperatures outside this range.
How is Imukin administered to patients?+
Imukin is supplied as a lyophilized powder for injection. After reconstitution with the appropriate diluent, it is administered subcutaneously by a healthcare professional according to the prescribing information and the patient’s individualized dosing schedule.
What are the most serious risks associated with Imukin therapy?+
Serious risks include hematologic abnormalities such as neutropenia or anemia, significant liver enzyme elevations, autoimmune reactions (e.g., lupus‑like syndrome), severe allergic responses including anaphylaxis, and pulmonary toxicity. Patients should be monitored regularly for these events.
Who should not receive Imukin?+
Imukin is contraindicated in individuals with known hypersensitivity to interferon‑gamma or any excipients in the formulation. Caution is advised for patients with severe cardiac disease, active autoimmune disorders, or those receiving live vaccines, as these conditions may increase the risk of adverse outcomes.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Recombinant Human Interferon Gamma 1b
Route
Subcutaneous Use
Manufacturer
Clinigen Healthcare B.V.
Origin
EU

Related products

Immukin

Immukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare Ltd
EU
Immukine

Immukine

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU
Imukin

Imukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU
Imukin

Imukin

Recombinant Human Interferon Gamma 1b

Clinigen Healthcare B.V.
EU